Difference between revisions of "Epoetin alfa (Procrit)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf Epoetin alfa (Procrit) package insert]</ref><ref>[[Media:Epoetin.pdf | Epoetin alfa (Procrit) package insert (locally hosted backup)]]</ref><ref>[http://www.procrit.com Procrit manufacturer's website]</ref> | + | Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.<ref name="insert">[http://www.procrit.com/shared/product/procrit/procrit-prescribing-information.pdf Epoetin alfa (Procrit) package insert]</ref><ref>[[Media:Epoetin.pdf | Epoetin alfa (Procrit) package insert (locally hosted backup)]]</ref><ref>[http://www.procrit.com Procrit manufacturer's website]</ref><ref>As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program</ref> |
<br>Route: SC, IV | <br>Route: SC, IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
Revision as of 05:28, 14 April 2017
General information
Class/mechanism: Erythropoiesis-stimulating agent (ESA), stimulates division and differentiation of erythroid precursors.[1][2][3][4]
Route: SC, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Epoetin alfa (Procrit) patient instructions for use[5][6]
- Brief patient counseling information can be found in the Epoetin alfa (Procrit) package insert[1]
- Epoetin alfa (Procrit) patient drug information (Chemocare)[7]
- Epoetin alfa (Procrit) patient drug information (UpToDate)[8]
History of changes in FDA indication
- 6/1/1989: Initial FDA approval
Also known as
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Ceriton | Dynepo | Epoch | Epoetin | Epoetin Alfa | Epoetin Beta | Epoetin Delta | Epoetin Zeta |
| Epofer | Epogen | Epogin | Epoimmun | Epomax | Epopen | Epox | Epoyet |
| Eprex | Eritrelan | Erypo | Erypo FS | Erythropoetin | Erythropoietin | Erythropoietin Human | Erythrostim |
| Espo | Espo Kirin | Espo Sankyo | Globuren | Hemapo | Hemax | KE Long YI BAO | LG Espogen |
| Procrit | Recormon | Recormon N | Recormon NEU | Recormon PS | Recormon S | Recormon SE | Vepox |
| Vintor | Wepox | ||||||
References
- ↑ 1.0 1.1 1.2 Epoetin alfa (Procrit) package insert
- ↑ Epoetin alfa (Procrit) package insert (locally hosted backup)
- ↑ Procrit manufacturer's website
- ↑ As of 4/14/2017, use of this medication in patients with oncologic diagnoses no longer requires enrollment in the ESA APPRISE Risk Evaluation and Mitigation Strategy (REMS) Program
- ↑ Epoetin alfa (Procrit) patient instructions for use
- ↑ Epoetin alfa (Procrit) patient instructions for use (locally hosted backup)
- ↑ Epoetin alfa (Procrit) patient drug information (Chemocare)
- ↑ Epoetin alfa (Procrit) patient drug information (UpToDate)